Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Hits New 1-Year Low – What’s Next?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY)’s stock price reached a new 52-week low on Tuesday . The stock traded as low as $6.69 and last traded at $6.76, with a volume of 1245038 shares trading hands. The stock had previously closed at $6.80.

Analyst Ratings Changes

Separately, Bank of America upgraded shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a report on Friday, September 6th. One analyst has rated the stock with a sell rating and eight have given a hold rating to the company’s stock. According to MarketBeat.com, Bayer Aktiengesellschaft currently has an average rating of “Hold”.

Bayer Aktiengesellschaft Trading Down 0.6 %

The company has a current ratio of 1.27, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. The business’s 50-day moving average is $7.60 and its two-hundred day moving average is $7.47. The firm has a market cap of $26.56 billion, a P/E ratio of -18.78 and a beta of 1.10.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.25 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.25. Bayer Aktiengesellschaft had a negative net margin of 2.74% and a positive return on equity of 16.96%. The business had revenue of $12 billion during the quarter. As a group, analysts expect that Bayer Aktiengesellschaft will post 1.38 earnings per share for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.